Indication intelligence, analysis and sector perception

RMi Research Note: Capricor Therapeutics (CAPR) overvalued, overbought and headed to a BIGGER slide

December 17, 2025 2:38pm

CAPR finally has a webinar to explain its recent P3 results, after dramatic equity flip-flops and today’s pricing drops!

Maintaining MY opinion and conviction; I STILL believe CAPR is Humpty-Dumpty

Capricor Therapeutics (CAPR) opened up +$0.64 on Wednesday was down -$0.01, at 3 pm and closed at +$0.13 after Tuesday’s -$0.53 while diving <-$4.36 in 6 sessions> a little late to have had a webinar, after announcing their P3 pr, instead of “clueing-in” bankers before INVESTORS! SEC anyone …!!

Right again! I f had been reading the daily, you would have known their limitations!

I would also ask if the SEC should investigate the post news run-up and the sudden offering financing pricing … 12/2 pricing = $6.36, 12/3 P3 results PR, 12/4 offering price of $25.00 to today’s … $26.01 so far?

Desperate times influenced a “sudden” Wednesday webinar!

CAPR should have had this webinar EARLIER, after announcing their P3 pr, instead of “clueing-in” bankers before INVESTORS! SEC anyone …!!

I believe CAPR got some “friendly” brokers to PROP and BUY; yet how long this HIGH last???

CAPR STILL has MANY remaining risks are tied to HOPE-3 and “upcoming” priority review?

Make your own decision to CUT-BACK as regulatory moving pieces will shape the investment narrative

Investors may wish to stay informed to better track and interpret future shifts in CAPR's soon to be evolving story – can you afford to wait and possibly take a hit out-of-the-blue.

HEDGE your RISK, it will travel down … waiting for the FDA which has had past and present questions!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 15 min ago
RMi Closing Bell: Rattled

3 hours 37 min ago
RMi Research Note: Capricor Therapeutics (CAPR) overvalued, overbought and headed to a BIGGER slide

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.